annotation_id large_string | subject large_string | rsid large_string | gene large_string | genotype large_string | evidence_level large_string | phenotype_category large_string | drugs large_string | phenotypes large_string | annotation_text large_string | url large_string |
|---|---|---|---|---|---|---|---|---|---|---|
981204466 | rs1045642 | rs1045642 | ABCB1 | AG | 3 | Toxicity | capecitabine | Neoplasms | Patients with AG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and g... | https://www.clinpgx.org/clinicalAnnotation/981204466 |
981204466 | rs1045642 | rs1045642 | ABCB1 | GG | 3 | Toxicity | capecitabine | Neoplasms | Patients with GG genotype may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and g... | https://www.clinpgx.org/clinicalAnnotation/981204466 |
981204525 | rs1801131 | rs1801131 | MTHFR | GG | 3 | Efficacy | bevacizumab;carboplatin;cisplatin;cyanocobalamin;folic acid;pemetrexed | Neoplasms | Genotype GG may be associated with overall survival and progression free survival in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype TT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a p... | https://www.clinpgx.org/clinicalAnnotation/981204525 |
981204525 | rs1801131 | rs1801131 | MTHFR | GT | 3 | Efficacy | bevacizumab;carboplatin;cisplatin;cyanocobalamin;folic acid;pemetrexed | Neoplasms | Genotype GT may be associated with overall survival and progression free survival in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype TT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a p... | https://www.clinpgx.org/clinicalAnnotation/981204525 |
981204525 | rs1801131 | rs1801131 | MTHFR | TT | 3 | Efficacy | bevacizumab;carboplatin;cisplatin;cyanocobalamin;folic acid;pemetrexed | Neoplasms | Genotype TT may be associated with overall survival and progression free survival in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype GG and GT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influe... | https://www.clinpgx.org/clinicalAnnotation/981204525 |
981204549 | rs1799752 | rs1799752 | ACE | ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC | 3 | Efficacy | hydrochlorothiazide | Essential hypertension | Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype and essential hypertension who are treated with hydrochlorothiazide may have a decreased reduction in blood pressure as compared to patients with the del/del genotype. The opposite associatio... | https://www.clinpgx.org/clinicalAnnotation/981204549 |
981204549 | rs1799752 | rs1799752 | ACE | ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del | 3 | Efficacy | hydrochlorothiazide | Essential hypertension | Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype and essential hypertension who are treated with hydrochlorothiazide may have a decreased reduction in blood pressure as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's resp... | https://www.clinpgx.org/clinicalAnnotation/981204549 |
981204549 | rs1799752 | rs1799752 | ACE | del/del | 3 | Efficacy | hydrochlorothiazide | Essential hypertension | Patients with the del/del genotype and essential hypertension who are treated with hydrochlorothiazide may have an increased reduction in blood pressure as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGAC... | https://www.clinpgx.org/clinicalAnnotation/981204549 |
981204641 | rs1799971 | rs1799971 | OPRM1 | AA | 3 | Toxicity | ethanol | null | Patients with the rs1799971 AA genotype may have a decreased, but not absent, severity of intoxication and a decreased response to ethanol as compared to patients with the AG and GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ethanol. | https://www.clinpgx.org/clinicalAnnotation/981204641 |
981204641 | rs1799971 | rs1799971 | OPRM1 | AG | 3 | Toxicity | ethanol | null | Patients with the rs1799971 AG genotype may have an increased severity of intoxication and an increased response when exposed to ethanol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ethanol. | https://www.clinpgx.org/clinicalAnnotation/981204641 |
981204641 | rs1799971 | rs1799971 | OPRM1 | GG | 3 | Toxicity | ethanol | null | Patients with the rs1799971 GG genotype may have an increased severity of intoxication and an increased response when exposed to ethanol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to ethanol. | https://www.clinpgx.org/clinicalAnnotation/981204641 |
981204695 | rs1799971 | rs1799971 | OPRM1 | AA | 4 | Efficacy | naltrexone | Alcohol abuse;Amplification of sexual behavior;Tobacco Use Disorder | The current evidence base suggests that there is no significant association between the rs1799971 AA genotype and response to naltrexone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other g... | https://www.clinpgx.org/clinicalAnnotation/981204695 |
981204695 | rs1799971 | rs1799971 | OPRM1 | AG | 4 | Efficacy | naltrexone | Alcohol abuse;Amplification of sexual behavior;Tobacco Use Disorder | The current evidence base suggests that there is no significant association between the rs1799971 AG genotype and response to naltrexone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other g... | https://www.clinpgx.org/clinicalAnnotation/981204695 |
981204695 | rs1799971 | rs1799971 | OPRM1 | GG | 4 | Efficacy | naltrexone | Alcohol abuse;Amplification of sexual behavior;Tobacco Use Disorder | The current evidence base suggests that there is no significant association between the rs1799971 GG genotype and response to naltrexone. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other g... | https://www.clinpgx.org/clinicalAnnotation/981204695 |
981204774 | rs1799971 | rs1799971 | OPRM1 | AA | 4 | Efficacy | Drugs used in nicotine dependence;nicotine | Tobacco Use Disorder | Patients with AA genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AG and GG genotype. However, contradictory findings reporting the opposite association for this genotype with decreased likelihood ... | https://www.clinpgx.org/clinicalAnnotation/981204774 |
981204774 | rs1799971 | rs1799971 | OPRM1 | AG | 4 | Efficacy | Drugs used in nicotine dependence;nicotine | Tobacco Use Disorder | Patients with AG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AA genotype. However, contradictory findings reporting the opposite association for this genotype with increased likelihood of smoki... | https://www.clinpgx.org/clinicalAnnotation/981204774 |
981204774 | rs1799971 | rs1799971 | OPRM1 | GG | 4 | Efficacy | Drugs used in nicotine dependence;nicotine | Tobacco Use Disorder | Patients with GG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy (transdermal nicotine patch) as compared to patients with the AA genotype. However, contradictory findings reporting the opposite association for this genotype with increased likelihood of smoki... | https://www.clinpgx.org/clinicalAnnotation/981204774 |
981204851 | rs1800497 | rs1800497 | ANKK1 | AA | 3 | Efficacy | nicotine | Tobacco Use Disorder | Patients with AA genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the GG genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation. | https://www.clinpgx.org/clinicalAnnotation/981204851 |
981204851 | rs1800497 | rs1800497 | ANKK1 | AG | 3 | Efficacy | nicotine | Tobacco Use Disorder | Patients with AG genotype may have an increased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the GG genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patient's likelihood of smoking cessation. | https://www.clinpgx.org/clinicalAnnotation/981204851 |
981204851 | rs1800497 | rs1800497 | ANKK1 | GG | 3 | Efficacy | nicotine | Tobacco Use Disorder | Patients with GG genotype may have a decreased likelihood of smoking cessation when treated with nicotine replacement therapy as compared to patients with the AG and AA genotype. However, contradictory findings have been reported. Other genetic and clinical factors may influence a patient's likelihood of smoking cessat... | https://www.clinpgx.org/clinicalAnnotation/981204851 |
981204864 | rs1801131 | rs1801131 | MTHFR | GG | 3 | Efficacy | capecitabine;fluorouracil;leucovorin;oxaliplatin | Neoplasms | Patients with the GG genotype who have cancer may have an increased response to fluoropyrimidine-based chemotherapy as compared to patients with the TT genotype. However, there is conflicting evidence with regards to the association between this variant and event-free survival. Fluoropyrimidines are often used in combi... | https://www.clinpgx.org/clinicalAnnotation/981204864 |
981204864 | rs1801131 | rs1801131 | MTHFR | GT | 3 | Efficacy | capecitabine;fluorouracil;leucovorin;oxaliplatin | Neoplasms | Patients with the GT genotype who have cancer may have an increased response to fluoropyrimidine-based chemotherapy as compared to patients with the TT genotype. However, there is conflicting evidence with regards to the association between this variant and event-free survival. Fluoropyrimidines are often used in combi... | https://www.clinpgx.org/clinicalAnnotation/981204864 |
981204864 | rs1801131 | rs1801131 | MTHFR | TT | 3 | Efficacy | capecitabine;fluorouracil;leucovorin;oxaliplatin | Neoplasms | Patients with the TT genotype who have cancer may have a decreased response to fluoropyrimidine-based chemotherapy as compared to patients with the GG or GT genotypes. However, there is conflicting evidence with regards to the association between this variant and event-free survival. Fluoropyrimidines are often used in... | https://www.clinpgx.org/clinicalAnnotation/981204864 |
981204874 | rs16969968 | rs16969968 | CHRNA5 | AA | 3 | Efficacy | bupropion;Drugs used in nicotine dependence;nicotine;varenicline | Tobacco Use Disorder | Patients with the AA genotype may more likely to respond to drugs to treat nicotine dependence as compared to patients with the GG genotype. However, several studies have not found this association and findings are somewhat contradictory in one study which performed haplotype analysis. Other genetic and clinical factor... | https://www.clinpgx.org/clinicalAnnotation/981204874 |
981204874 | rs16969968 | rs16969968 | CHRNA5 | AG | 3 | Efficacy | bupropion;Drugs used in nicotine dependence;nicotine;varenicline | Tobacco Use Disorder | Patients with the AG genotype may more likely to respond to drugs to treat nicotine dependence as compared to patients with the GG genotype. However, several studies have not found this association and findings are somewhat contradictory in one study which performed haplotype analysis. Other genetic and clinical factor... | https://www.clinpgx.org/clinicalAnnotation/981204874 |
981204874 | rs16969968 | rs16969968 | CHRNA5 | GG | 3 | Efficacy | bupropion;Drugs used in nicotine dependence;nicotine;varenicline | Tobacco Use Disorder | Patients with the GG genotype may less likely to respond to drugs to treat nicotine dependence as compared to patients with the AA or AG genotypes. However, several studies have not found this association and findings are somewhat contradictory in one study which performed haplotype analysis. Other genetic and clinical... | https://www.clinpgx.org/clinicalAnnotation/981204874 |
981204890 | rs1800497 | rs1800497 | ANKK1;DRD2 | AA | 3 | Toxicity | ethanol | Alcohol abuse | Patients with AA genotype may have an increased risk for Alcoholism when exposed to ethanol as compared to patients with the GG genotype. However, other studies have found no association. Other genetic and clinical factors may influence a patient's risk for alcohol dependency. | https://www.clinpgx.org/clinicalAnnotation/981204890 |
981204890 | rs1800497 | rs1800497 | ANKK1;DRD2 | AG | 3 | Toxicity | ethanol | Alcohol abuse | Patients with AG genotype may have an increased risk for Alcoholism when exposed to ethanol as compared to patients with the GG genotype. However, other studies have found no association. Other genetic and clinical factors may influence a patient's risk for alcohol dependency. | https://www.clinpgx.org/clinicalAnnotation/981204890 |
981204890 | rs1800497 | rs1800497 | ANKK1;DRD2 | GG | 3 | Toxicity | ethanol | Alcohol abuse | Patients with GG genotype may have a decreased, but not absent, risk for Alcoholism when exposed to ethanol as compared to patients with the AG and AA genotype. However, other studies have found no association. Other genetic and clinical factors may influence a patient's risk for alcohol dependency. | https://www.clinpgx.org/clinicalAnnotation/981204890 |
981204902 | rs16969968 | rs16969968 | CHRNA5 | AA | 2B | Toxicity | nicotine | Tobacco Use Disorder | Patients with rs16969968 AA genotype may have an increased risk for nicotine dependence when exposed to nicotine as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Some findings are based on haplotype studies with either rs680244 or rs680244, rs569207 rs578776, and rs1... | https://www.clinpgx.org/clinicalAnnotation/981204902 |
981204902 | rs16969968 | rs16969968 | CHRNA5 | AG | 2B | Toxicity | nicotine | Tobacco Use Disorder | Patients with rs16969968 AG genotype may have an increased risk for nicotine dependence when exposed to nicotine as compared to patients with the GG genotype, but a decreased risk as compared to patients with the AA genotype. However, conflicting evidence has been reported. Some findings are based on haplotype studies ... | https://www.clinpgx.org/clinicalAnnotation/981204902 |
981204902 | rs16969968 | rs16969968 | CHRNA5 | GG | 2B | Toxicity | nicotine | Tobacco Use Disorder | Patients with rs16969968 GG genotype may have a decreased, but not absent, risk for nicotine dependence when exposed to nicotine as compared to patients with the AG or AA genotypes. However, conflicting evidence has been reported. Some findings are based on haplotype studies with either rs680244 or rs680244, rs569207 r... | https://www.clinpgx.org/clinicalAnnotation/981204902 |
981204912 | rs1801133 | rs1801133 | MTHFR | AA | 4 | Toxicity | capecitabine;fluorouracil | Neoplasms | Cancer patients with the AA genotype may have increased risk of drug toxicities when treated with fluorouracil- or capecitabine-based therapy as compared to patients with the AG or GG genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk of ... | https://www.clinpgx.org/clinicalAnnotation/981204912 |
981204912 | rs1801133 | rs1801133 | MTHFR | AG | 4 | Toxicity | capecitabine;fluorouracil | Neoplasms | Cancer patients with the AG genotype may have increased risk of drug toxicities when treated with fluorouracil- or capecitabine-based therapy as compared to patients with the GG genotype, or a decreased risk of drug toxicities as compared to patients with the AA genotype. This has been contradicted in some studies. Oth... | https://www.clinpgx.org/clinicalAnnotation/981204912 |
981204912 | rs1801133 | rs1801133 | MTHFR | GG | 4 | Toxicity | capecitabine;fluorouracil | Neoplasms | Cancer patients with the GG genotype may have a decreased risk of drug toxicities when treated with fluorouracil- or capecitabine-based therapy as compared to patients with the AA or AG genotype, however this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk o... | https://www.clinpgx.org/clinicalAnnotation/981204912 |
981204941 | rs1801019 | rs1801019 | UMPS | CC | 3 | Toxicity | tegafur | Drug Toxicity | Patients with CC genotype and cancer may have an increased risk for toxicity when treated with tegafur as compared to patients with the CG and GG genotype. Other genetic and clinical factors may also influence tegafur toxicity. | https://www.clinpgx.org/clinicalAnnotation/981204941 |
981204941 | rs1801019 | rs1801019 | UMPS | CG | 3 | Toxicity | tegafur | Drug Toxicity | Patients with CG genotype and cancer may have a decreased risk for toxicity when treated with tegafur as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tegafur toxicity. | https://www.clinpgx.org/clinicalAnnotation/981204941 |
981204941 | rs1801019 | rs1801019 | UMPS | GG | 3 | Toxicity | tegafur | Drug Toxicity | Patients with GG genotype and cancer may have a decreased risk for toxicity when treated with tegafur as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tegafur toxicity. | https://www.clinpgx.org/clinicalAnnotation/981204941 |
981204975 | rs1801133 | rs1801133 | MTHFR | AA | 4 | Toxicity | mercaptopurine | Acute lymphoblastic leukemia | Patients with the AA genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also in... | https://www.clinpgx.org/clinicalAnnotation/981204975 |
981204975 | rs1801133 | rs1801133 | MTHFR | AG | 4 | Toxicity | mercaptopurine | Acute lymphoblastic leukemia | Patients with the AG genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also in... | https://www.clinpgx.org/clinicalAnnotation/981204975 |
981204975 | rs1801133 | rs1801133 | MTHFR | GG | 4 | Toxicity | mercaptopurine | Acute lymphoblastic leukemia | Patients with the GG genotype may have decreased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype AA or AG. However, contradictory finding has been reported. Other genetic and clinical factors may a... | https://www.clinpgx.org/clinicalAnnotation/981204975 |
981204995 | rs1799793 | rs1799793 | ERCC2 | CC | 4 | Efficacy;Toxicity | Platinum compounds | Neoplasms | Patients with the CC genotype and cancer who are treated with platinum-based chemotherapy may have shorter survival times as compared to patients with the CT or TT genotype. This has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to platinum-based chemothe... | https://www.clinpgx.org/clinicalAnnotation/981204995 |
981204995 | rs1799793 | rs1799793 | ERCC2 | CT | 4 | Efficacy;Toxicity | Platinum compounds | Neoplasms | Patients with the CT genotype and cancer who are treated with platinum-based chemotherapy may have longer survival times as compared to patients with the CC genotype. This has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy. | https://www.clinpgx.org/clinicalAnnotation/981204995 |
981204995 | rs1799793 | rs1799793 | ERCC2 | TT | 4 | Efficacy;Toxicity | Platinum compounds | Neoplasms | Patients with the TT genotype and cancer who are treated with platinum-based chemotherapy may have longer survival times as compared to patients with the CC genotype. This has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy. | https://www.clinpgx.org/clinicalAnnotation/981204995 |
981220481 | rs1801133 | rs1801133 | MTHFR | AA | 3 | Toxicity | cisplatin;oxaliplatin;Platinum compounds | Neoplasms | Patients with AA genotype may have an increased risk of drug toxicity when treated with platinum drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity when receiving platinum-based chemotherapy. | https://www.clinpgx.org/clinicalAnnotation/981220481 |
981220481 | rs1801133 | rs1801133 | MTHFR | AG | 3 | Toxicity | cisplatin;oxaliplatin;Platinum compounds | Neoplasms | Patients with AG genotype may have a decreased risk of drug toxicity when treated with platinum drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity when receiving platinum-based chemotherapy. | https://www.clinpgx.org/clinicalAnnotation/981220481 |
981220481 | rs1801133 | rs1801133 | MTHFR | GG | 3 | Toxicity | cisplatin;oxaliplatin;Platinum compounds | Neoplasms | Patients with GG genotype may have a decreased risk of drug toxicity when treated with platinum drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity when receiving platinum-based chemotherapy. | https://www.clinpgx.org/clinicalAnnotation/981220481 |
981237695 | rs17222723 | rs17222723 | ABCC2 | AA | 3 | Toxicity | tenofovir | HIV infectious disease | Patients with the AA genotype and HIV who are treated with tenofovir may have a decreased risk of renal proximal tubulopathy as compared to patients with the TT genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's risk for adverse events wi... | https://www.clinpgx.org/clinicalAnnotation/981237695 |
981237695 | rs17222723 | rs17222723 | ABCC2 | AT | 3 | Toxicity | tenofovir | HIV infectious disease | Patients with the AT genotype and HIV who are treated with tenofovir may have a decreased risk of renal proximal tubulopathy as compared to patients with the TT genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's risk for adverse events wi... | https://www.clinpgx.org/clinicalAnnotation/981237695 |
981237695 | rs17222723 | rs17222723 | ABCC2 | TT | 3 | Toxicity | tenofovir | HIV infectious disease | Patients with the TT genotype and HIV who are treated with tenofovir may have an increased risk of renal proximal tubulopathy as compared to patients with the AT and AA genotype. This association has been contradicted in other studies. Other genetic and clinical factors may also influence a patient's risk for adverse e... | https://www.clinpgx.org/clinicalAnnotation/981237695 |
981237704 | rs1805087 | rs1805087 | MTR | AA | 4 | Toxicity | methotrexate | Acute lymphoblastic leukemia;Brain Diseases;Drug Toxicity;Osteosarcoma | The current evidence base suggests that there is no significant association between the rs1805087 AA genotype and risk of toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate. | https://www.clinpgx.org/clinicalAnnotation/981237704 |
981237704 | rs1805087 | rs1805087 | MTR | AG | 4 | Toxicity | methotrexate | Acute lymphoblastic leukemia;Brain Diseases;Drug Toxicity;Osteosarcoma | The current evidence base suggests that there is no significant association between the rs1805087 AG genotype and risk of toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate. | https://www.clinpgx.org/clinicalAnnotation/981237704 |
981237704 | rs1805087 | rs1805087 | MTR | GG | 4 | Toxicity | methotrexate | Acute lymphoblastic leukemia;Brain Diseases;Drug Toxicity;Osteosarcoma | The current evidence base suggests that there is no significant association between the rs1805087 GG genotype and risk of toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity when treated with methotrexate. | https://www.clinpgx.org/clinicalAnnotation/981237704 |
981237713 | rs1805087 | rs1805087 | MTR | AA | 3 | Efficacy;Toxicity | carboplatin;cisplatin | Neoplasms | Patients with the AA genotype and cancer may have a decreased risk for drug toxicity and a decreased response to treatment with cisplatin or carboplatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity and response to platinum-based chemot... | https://www.clinpgx.org/clinicalAnnotation/981237713 |
981237713 | rs1805087 | rs1805087 | MTR | AG | 3 | Efficacy;Toxicity | carboplatin;cisplatin | Neoplasms | Patients with the AG genotype and cancer may have a decreased risk for drug toxicity and a decreased response to treatment with cisplatin or carboplatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity and response to platinum-based chemot... | https://www.clinpgx.org/clinicalAnnotation/981237713 |
981237713 | rs1805087 | rs1805087 | MTR | GG | 3 | Efficacy;Toxicity | carboplatin;cisplatin | Neoplasms | Patients with the GG genotype and cancer may have an increased risk for drug toxicity and an increased response to treatment with cisplatin or carboplatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity and response to platinum-base... | https://www.clinpgx.org/clinicalAnnotation/981237713 |
981237871 | rs11045585 | rs11045585 | SLCO1B3 | AA | 3 | Toxicity | docetaxel | Neoplasms | Patients with the AA genotype and Neoplasms who are treated with docetaxel may have 1) a decreased, but not absent, risk of leukopenia, 2) an increased clearance of docetaxel as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to docetaxel. | https://www.clinpgx.org/clinicalAnnotation/981237871 |
981237871 | rs11045585 | rs11045585 | SLCO1B3 | AG | 3 | Toxicity | docetaxel | Neoplasms | Patients with the AG genotype and Neoplasms who are treated with docetaxel may have 1) an increased risk of leukopenia, 2) a decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to docetaxel. | https://www.clinpgx.org/clinicalAnnotation/981237871 |
981237871 | rs11045585 | rs11045585 | SLCO1B3 | GG | 3 | Toxicity | docetaxel | Neoplasms | Patients with the GG genotype and Neoplasms who are treated with docetaxel may have 1) an increased risk of leukopenia, 2) a decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to docetaxel. | https://www.clinpgx.org/clinicalAnnotation/981237871 |
981237878 | rs1105879 | rs1105879 | UGT1A6 | AA | 3 | Dosage | valproic acid | Epilepsy | Patients with the AA genotype and Epilepsy who are treated with valproic acid may require a decreased dose as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to valproic acid. | https://www.clinpgx.org/clinicalAnnotation/981237878 |
981237878 | rs1105879 | rs1105879 | UGT1A6 | AC | 3 | Dosage | valproic acid | Epilepsy | Patients with the AC genotype and Epilepsy who are treated with valproic acid may require an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to valproic acid. | https://www.clinpgx.org/clinicalAnnotation/981237878 |
981237878 | rs1105879 | rs1105879 | UGT1A6 | CC | 3 | Dosage | valproic acid | Epilepsy | Patients with the CC genotype and Epilepsy who are treated with valproic acid may require an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to valproic acid. | https://www.clinpgx.org/clinicalAnnotation/981237878 |
981237900 | rs11212617 | rs11212617 | ATM;C11orf65 | AA | 4 | Efficacy | metformin | Diabetes Mellitus, Type 2 | Patients with the AA genotype with diabetes mellitus or polycystic ovarian syndrome who are treated with metformin may have a decreased response to metformin as compared to patients with the CC genotype. An association with increased/decreased response to metformin was not seen in people with impaired glucose tolerance... | https://www.clinpgx.org/clinicalAnnotation/981237900 |
981237900 | rs11212617 | rs11212617 | ATM;C11orf65 | AC | 4 | Efficacy | metformin | Diabetes Mellitus, Type 2 | Patients with the AC genotype with diabetes mellitus, or polycystic ovarian syndrome who are treated with metformin may have an increased response to metformin as compared to patients with the AA genotype or may have a decreased response to metformin as compared to patients with the CC genotype. An association with inc... | https://www.clinpgx.org/clinicalAnnotation/981237900 |
981237900 | rs11212617 | rs11212617 | ATM;C11orf65 | CC | 4 | Efficacy | metformin | Diabetes Mellitus, Type 2 | Patients with the CC genotype with diabetes mellitus, or polycystic ovarian syndrome who are treated with metformin may have an increased response to metformin as compared to patients with the AA genotype. An association with increased/decreased response to metformin was not seen in people with impaired glucose toleran... | https://www.clinpgx.org/clinicalAnnotation/981237900 |
981237907 | rs1127354 | rs1127354 | ITPA | AA | 3 | Dosage | interferon alfa-2b, recombinant;ribavirin | Chronic hepatitis C virus infection | Patients with the AA genotype and chronic hepatitis C may not require a dose reduction of ribavirin when treated with recombinant interferon alfa-2b and ribavirin, or recombinant interferon alfa-2b, ribavirin, and telaprevir as compared to patients with the CC genotype. Other genetic and clinical factors may also influ... | https://www.clinpgx.org/clinicalAnnotation/981237907 |
981237907 | rs1127354 | rs1127354 | ITPA | AC | 3 | Dosage | interferon alfa-2b, recombinant;ribavirin | Chronic hepatitis C virus infection | Patients with the AC genotype and chronic hepatitis C may not require a dose reduction or ribavirin when treated with recombinant interferon alfa-2b and ribavirin, or recombinant interferon alfa-2b, ribavirin and telaprevir, as compared to patients with the CC genotype. Other genetic and clinical factors may also influ... | https://www.clinpgx.org/clinicalAnnotation/981237907 |
981237907 | rs1127354 | rs1127354 | ITPA | CC | 3 | Dosage | interferon alfa-2b, recombinant;ribavirin | Chronic hepatitis C virus infection | Patients with the CC genotype and chronic hepatitis C may require a dose reduction of ribavirin when treated with recombinant interferon alfa-2b and ribavirin, or recombinant interferon alfa-2b, ribavirin and telaprevir, as compared to patients with the AC and AA genotype. Other genetic and clinical factors may also in... | https://www.clinpgx.org/clinicalAnnotation/981237907 |
981237922 | rs1128503 | rs1128503 | ABCB1 | AA | 3 | Other | phenytoin | null | Patients with the AA genotype who receive phenytoin may have increased plasma drug levels of phenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin. | https://www.clinpgx.org/clinicalAnnotation/981237922 |
981237922 | rs1128503 | rs1128503 | ABCB1 | AG | 3 | Other | phenytoin | null | Patients with the AG genotype who receive phenytoin may have increased plasma drug levels of phenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin. | https://www.clinpgx.org/clinicalAnnotation/981237922 |
981237922 | rs1128503 | rs1128503 | ABCB1 | GG | 3 | Other | phenytoin | null | Patients with the GG genotype who receive phenytoin may have decreased plasma drug levels of phenytoin as compared to patients with the AG and AA genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin. | https://www.clinpgx.org/clinicalAnnotation/981237922 |
981237930 | rs11615 | rs11615 | ERCC1 | AA | 3 | Toxicity | cisplatin;cyclophosphamide | Ovarian Neoplasms | Genotype AA is not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide as compared to genotypes AG and GG. Please note, patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk of nephrotoxicity as com... | https://www.clinpgx.org/clinicalAnnotation/981237930 |
981237930 | rs11615 | rs11615 | ERCC1 | AG | 3 | Toxicity | cisplatin;cyclophosphamide | Ovarian Neoplasms | Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk of nephrotoxicity as compared to patients with the GG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's ris... | https://www.clinpgx.org/clinicalAnnotation/981237930 |
981237930 | rs11615 | rs11615 | ERCC1 | GG | 3 | Toxicity | cisplatin;cyclophosphamide | Ovarian Neoplasms | Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased, but not absent, risk of nephrotoxicity as compared to patients with the AG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence... | https://www.clinpgx.org/clinicalAnnotation/981237930 |
981237950 | rs1695 | rs1695 | GSTP1 | AA | 3 | Efficacy | cisplatin;cyclophosphamide | Ovarian Neoplasms | Patients with the AA genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased likelihood of progression free survival as compared to patients with the AG and GG genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may a... | https://www.clinpgx.org/clinicalAnnotation/981237950 |
981237950 | rs1695 | rs1695 | GSTP1 | AG | 3 | Efficacy | cisplatin;cyclophosphamide | Ovarian Neoplasms | Patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also infl... | https://www.clinpgx.org/clinicalAnnotation/981237950 |
981237950 | rs1695 | rs1695 | GSTP1 | GG | 3 | Efficacy | cisplatin;cyclophosphamide | Ovarian Neoplasms | Patients with the GG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased likelihood of progression free survival as compared to patients with the AA genotype. However, this association was contradicted in other studies. Other genetic and clinical factors may also infl... | https://www.clinpgx.org/clinicalAnnotation/981237950 |
981237959 | rs13181 | rs13181 | ERCC2 | GG | 3 | Efficacy;Toxicity | fluorouracil;leucovorin;oxaliplatin | Colorectal Neoplasms | Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity 2) an increased risk of early relapse and 3) decreased progression free survival as compared to patients with the TT genotype... | https://www.clinpgx.org/clinicalAnnotation/981237959 |
981237959 | rs13181 | rs13181 | ERCC2 | GT | 3 | Efficacy;Toxicity | fluorouracil;leucovorin;oxaliplatin | Colorectal Neoplasms | Patients with the GT genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or fluorouracil, leucovorin and oxaliplatin may have 1) an increased risk of Drug Toxicity as compared to patients with the TT genotype 2) an increased risk of early relapse as compared to patients with the TT genoty... | https://www.clinpgx.org/clinicalAnnotation/981237959 |
981237959 | rs13181 | rs13181 | ERCC2 | TT | 3 | Efficacy;Toxicity | fluorouracil;leucovorin;oxaliplatin | Colorectal Neoplasms | Patients with the TT genotype and Colorectal Neoplasms who are treated with fluorouracil and leucovorin or fluorouracil, leucovorin and oxaliplatin may have 1) a decreased, but not absent, risk of Drug Toxicity 2) a decreased, but not absent, risk of early relapse and 3) increased progression free survival as compared ... | https://www.clinpgx.org/clinicalAnnotation/981237959 |
981238025 | rs2032582 | rs2032582 | ABCB1 | CC | 3 | Efficacy | cyclophosphamide;doxorubicin | Breast Neoplasms | Patients with the CC genotype may have increased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CT or TT. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin. | https://www.clinpgx.org/clinicalAnnotation/981238025 |
981238025 | rs2032582 | rs2032582 | ABCB1 | CT | 3 | Efficacy | cyclophosphamide;doxorubicin | Breast Neoplasms | Patients with the CT genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin. | https://www.clinpgx.org/clinicalAnnotation/981238025 |
981238025 | rs2032582 | rs2032582 | ABCB1 | TT | 3 | Efficacy | cyclophosphamide;doxorubicin | Breast Neoplasms | Patients with the TT genotype may have decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotypes patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide and doxorubicin. | https://www.clinpgx.org/clinicalAnnotation/981238025 |
981238041 | rs2032582 | rs2032582 | ABCB1 | AA | 3 | Efficacy | dexamethasone;doxorubicin;vincristine | Multiple Myeloma | Patients with the AA genotype are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to the therapy. | https://www.clinpgx.org/clinicalAnnotation/981238041 |
981238041 | rs2032582 | rs2032582 | ABCB1 | AC | 3 | Efficacy | dexamethasone;doxorubicin;vincristine | Multiple Myeloma | Patients with the AC genotype are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to the therapy. | https://www.clinpgx.org/clinicalAnnotation/981238041 |
981238041 | rs2032582 | rs2032582 | ABCB1 | CC | 3 | Efficacy | dexamethasone;doxorubicin;vincristine | Multiple Myeloma | Patients with the CC genotype are associated with decreased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence patient's response to the therapy. | https://www.clinpgx.org/clinicalAnnotation/981238041 |
981238057 | rs2032582 | rs2032582 | ABCB1 | AA | 3 | Other | doxorubicin | Breast Neoplasms | Patients with the AA genotype may have decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of doxorubicin. | https://www.clinpgx.org/clinicalAnnotation/981238057 |
981238057 | rs2032582 | rs2032582 | ABCB1 | AC | 3 | Other | doxorubicin | Breast Neoplasms | Patients with the AC genotype may have decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of doxorubicin. | https://www.clinpgx.org/clinicalAnnotation/981238057 |
981238057 | rs2032582 | rs2032582 | ABCB1 | CC | 3 | Other | doxorubicin | Breast Neoplasms | Patients with the CC genotype may have increased metabolism of doxorubicin in people with Breast Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the metabolism of doxorubicin. | https://www.clinpgx.org/clinicalAnnotation/981238057 |
981238092 | rs2032582 | rs2032582 | ABCB1 | AA | 3 | Dosage;Efficacy | antiepileptics;carbamazepine | Epilepsy | Patients with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AA is not associated with dose of carbamazepine. Other genetic and ... | https://www.clinpgx.org/clinicalAnnotation/981238092 |
981238092 | rs2032582 | rs2032582 | ABCB1 | AC | 3 | Dosage;Efficacy | antiepileptics;carbamazepine | Epilepsy | Patients with genotype AC may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AC is not associated with dose of carbamazepine. Other genetic and ... | https://www.clinpgx.org/clinicalAnnotation/981238092 |
981238092 | rs2032582 | rs2032582 | ABCB1 | CC | 3 | Dosage;Efficacy | antiepileptics;carbamazepine | Epilepsy | Patients with genotype CC may have decreased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype AA. However, contradictory findings have been reported. Genotype CC is not associated with dose of carbamazepine. Other genetic and ... | https://www.clinpgx.org/clinicalAnnotation/981238092 |
981238108 | rs2032582 | rs2032582 | ABCB1 | AA | 3 | Other | digoxin | null | Patients with genotype AA may have decreased metabolism of digoxin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of digoxin. | https://www.clinpgx.org/clinicalAnnotation/981238108 |
981238108 | rs2032582 | rs2032582 | ABCB1 | AC | 3 | Other | digoxin | null | Patients with genotype AC may have increased metabolism of digoxin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the metabolism of digoxin. | https://www.clinpgx.org/clinicalAnnotation/981238108 |
981238108 | rs2032582 | rs2032582 | ABCB1 | CC | 3 | Other | digoxin | null | Patients with genotype CC may have increased metabolism of digoxin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the metabolism of digoxin. | https://www.clinpgx.org/clinicalAnnotation/981238108 |
981238234 | rs1360780 | rs1360780 | FKBP5 | CC | 3 | Toxicity | clomipramine;nefazodone;paroxetine;venlafaxine | Depression | Patients with the CC genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone have a decreased, but not absent, risk of suicidal ideation as compared to patients with the CT and TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine,... | https://www.clinpgx.org/clinicalAnnotation/981238234 |
981238234 | rs1360780 | rs1360780 | FKBP5 | CT | 3 | Toxicity | clomipramine;nefazodone;paroxetine;venlafaxine | Depression | Patients with the CT genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone may have an increased risk of suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomi... | https://www.clinpgx.org/clinicalAnnotation/981238234 |
981238234 | rs1360780 | rs1360780 | FKBP5 | TT | 3 | Toxicity | clomipramine;nefazodone;paroxetine;venlafaxine | Depression | Patients with the TT genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone may have an increased risk of suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomi... | https://www.clinpgx.org/clinicalAnnotation/981238234 |
981238288 | rs2032582 | rs2032582 | ABCB1 | AA | 4 | Efficacy | efavirenz | HIV infectious disease | Patients with the AA genotype may have decreased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to patients with the CC genotype.This varaint is not associated with plasma exposure of efavirenz. Other genetic and clinical factors may also influence the r... | https://www.clinpgx.org/clinicalAnnotation/981238288 |
981238288 | rs2032582 | rs2032582 | ABCB1 | AC | 4 | Efficacy | efavirenz | HIV infectious disease | Patients with the AC genotype may have decreased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to patients with the CC genotype.This varaint is not associated with plasma exposure of efavirenz. Other genetic and clinical factors may also influence the r... | https://www.clinpgx.org/clinicalAnnotation/981238288 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.